Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack without blockage: trial tests gentler blood thinners for SCAD

NCT ID NCT07683923

Disease control Sponsor: Universitätsklinikum Hamburg-Eppendorf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests whether a less intensive antiplatelet therapy is safer and as effective as standard dual therapy for people with spontaneous coronary artery dissection (SCAD), a rare cause of heart attack in women aged 30–55. Unlike typical heart attacks, SCAD involves a tear in the artery wall, so strong blood thinners might worsen bleeding. The study compares 3 months of a single drug versus 3 months of two drugs followed by 9 months of one drug, tracking heart events over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Acetylsalicylic acid (ASA) and clopidogrel
What this could lead to
If successful, this could establish a safer, more effective antiplatelet regimen for SCAD patients, reducing heart complications without worsening vessel bleeding.
What could go wrong
This is a Phase 4 trial, but SCAD is rare and understudied; results may not apply to all patients, and the less intensive strategy might not prevent clots as well.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 3,518 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2027

An estimate. Start dates often move.

Expected to finish

Feb 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years. 2. Presentation with an Acute Coronary Syndrome. 3. Suspected SCAD on coronary angiography (determined by the local investigator). 4. Planned conservative treatment of SCAD. 5. Intensive as well as moderate treatment of SCAD is possible. 6. Ability to understand the patient information and to personally sign and date the informed consent to participate in the study, before completing any study-related procedures. 7. The patient is cooperative and available for the entire study. 8. Written and informed consent. 9. For women of childbearing potential: Patient is willing to use adequate contraceptive precautions during the study (until 12 Month FU) Exclusion Criteria: 1. Hypersensitivity to the study medication. 2. Any indication for oral anticoagulation. 3. Any indication for APT (including thienopyridines, non-thienopyridines, ASA and other anti-thrombotic agents) other than SCAD. 4. Cardiogenic shock at the time of screening. 5. Coronary artery disease (CAD) requiring secondary preventive therapy with APT. 6. Life threatening bleeding (BARC type ≥3) at the time of screening. 7. Active bleeding, such as peptic ulcer, tumor bleeding or intracranial hemor-rhage at the time of screening. 8. History of major bleeding, BARC class ≥3 within 3 months before study in-clusion. 9. Known bleeding diathesis. 10. Known coagulopathy or refusal of blood transfusion. 11. Planned surgery or intervention at high bleeding risk during the study period. 12. Co-administration of contraindicated medications as follows: other P2Y12 inhibitors (prasugrel or ticagrelor); anticoagulants (warfarin, new oral antico-agulants, or chronic therapy with subcutaneous anticoagulants); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg/week); lithium. 13. Known pregnancy or lactation. 14. Current participation in another clinical trial with drugs or medicinal products.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acs (acute coronary syndrome) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute chest syndrome acute coronary syndrome idiopathic spontaneous coronary artery dissection short chain acyl-CoA dehydrogenase deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acs (acute coronary syndrome) SCAD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Cardiology and Department of Medical and Health Sciences, Linköping University

    Linköping, SE-581 83, Sweden

  • Division of Cardiology, St. Antonius Hospital

    Nieuwegein, 3435 CM, Netherlands

  • Division of Cardiology, Vancouver General Hospital, University of British Columbia

    Vancouver, British Columbia, V5Z 1M9, Canada

  • University Hospitals of Leicester NHS Trust

    Leicester, LE1 5WW, United Kingdom

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Free and Hanseatic City of Hamburg, 20246, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.